|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM286663422 |
| 003 |
DE-627 |
| 005 |
20231225052243.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2018 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2018.06.008
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0955.xml
|
| 035 |
|
|
|a (DE-627)NLM286663422
|
| 035 |
|
|
|a (NLM)30025819
|
| 035 |
|
|
|a (PII)S1521-6616(17)30877-X
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Jackson, Doreen O
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design
|
| 264 |
|
1 |
|c 2018
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 27.08.2019
|
| 500 |
|
|
|a Date Revised 27.08.2019
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a ClinicalTrials.gov: NCT00524277
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2018. Published by Elsevier Inc.
|
| 520 |
|
|
|a Immunotherapy, using peptide-based cancer vaccines is being studied to assess its potential in breast cancer. Trials of HLA-restricted peptide vaccines have been difficult to enroll given HLA subtype restrictions. It is necessary to determine the prognostic significance of HLA-status in breast cancer if patients who are ineligible to receive a vaccine due to their HLA-status are used as controls. The impact of targeted tumor associated antigen expression, when it effects eligibility is also important. We examined control patients from two randomized phase II trials that tested HER2-peptide vaccines to determine the effect of HLA-A2 status and HER2 expression on disease-free survival. The analysis showed that HLA-A2-status does not affect disease-free survival, regardless of HER2 expression suggesting that HLA-A2 negative patients can be used as control patients. Additionally, HER2 over-expression was associated with a better disease-free survival in this population, underscoring the need for additional therapies in HER2 low-expressing breast cancer. ClinicalTrials.gov Identifier: NCT00524277
|
| 650 |
|
4 |
|a Clinical Trial, Phase II
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Randomized Controlled Trial
|
| 650 |
|
4 |
|a Breast Cancer
|
| 650 |
|
4 |
|a HER2 expression
|
| 650 |
|
4 |
|a HLA-status
|
| 650 |
|
4 |
|a Immunotherapy
|
| 650 |
|
7 |
|a Cancer Vaccines
|2 NLM
|
| 650 |
|
7 |
|a HLA-A2 Antigen
|2 NLM
|
| 650 |
|
7 |
|a Vaccines, Subunit
|2 NLM
|
| 650 |
|
7 |
|a Granulocyte-Macrophage Colony-Stimulating Factor
|2 NLM
|
| 650 |
|
7 |
|a 83869-56-1
|2 NLM
|
| 650 |
|
7 |
|a ERBB2 protein, human
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.10.1
|2 NLM
|
| 650 |
|
7 |
|a Receptor, ErbB-2
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.10.1
|2 NLM
|
| 700 |
1 |
|
|a Trappey, Francois A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Clifton, G Travis
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Vreeland, Timothy J
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Peace, Kaitlin M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hale, Diane F
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Litton, Jennifer K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Murray, James L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Perez, Sonia A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Papamichail, Michael
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mittendorf, Elizabeth A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Peoples, George E
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 195(2018) vom: 05. Okt., Seite 28-35
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:195
|g year:2018
|g day:05
|g month:10
|g pages:28-35
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2018.06.008
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 195
|j 2018
|b 05
|c 10
|h 28-35
|